Welcome to our dedicated page for Myriad Genetics SEC filings (Ticker: MYGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Myriad Genetics Inc. filings document the regulatory record of a molecular diagnostics and precision medicine company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue and test-volume information, guidance, and product-related operating updates tied to Cancer Care Continuum, Prenatal Health, Mental Health, Precise MRD, and MyChoice CDx.
The company's proxy materials cover board matters, executive compensation, equity awards, and annual meeting governance. Other current reports document officer transitions, compensatory arrangements, and amendments to previously furnished earnings materials, providing formal disclosure of governance changes and financial-reporting corrections.
MYRIAD GENETICS INC President and CEO Samraat S. Raha acquired 3,542 shares of common stock on June 11, 2026. The shares were obtained at $3.936 per share under the company’s Amended and Restated 2012 Employee Stock Purchase Plan, as a compensation-related award.
After this acquisition, Raha directly holds 1,068,083 shares of Myriad Genetics common stock. This filing reflects a routine, plan-based share purchase rather than an open-market buy or sell decision.
Myriad Genetics Chief Commercial Officer Brian J. Donnelly acquired 5,000 shares of common stock through the company’s Amended and Restated 2012 Employee Stock Purchase Plan. The shares were acquired at a price of $3.936 per share in a transaction exempt under Rule 16b-3(d) and Rule 16b-3(c).
After this acquisition, Donnelly directly holds 573,363 shares of Myriad Genetics common stock, indicating this is a relatively small, routine, compensation-related increase in his overall equity position rather than an open-market purchase.
Myriad Genetics Inc. director Rashmi Kumar sold 15,000 shares of Common Stock in an open-market transaction. The shares were sold on 2026-06-08 at a weighted average price of $4.4562 per share, in multiple trades ranging from $4.37 to $4.63.
After this sale, Kumar directly owns 171,889 shares of Myriad Genetics Common Stock. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
Myriad Genetics director Daniel Skovronsky received an equity award of 59,701 shares of common stock in the form of restricted stock units. The grant was made at no cash cost to him and represents compensation rather than an open-market purchase.
Each restricted stock unit converts into one share of Myriad Genetics common stock and will vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant. After this award, Skovronsky holds a total of 195,507 shares of common stock directly.
Newcomer Lee Nisley reported acquisition or exercise transactions in this Form 4 filing.
Myriad Genetics director Lee Nisley Newcomer received a grant of restricted stock units. The Form 4 shows an award of 59,701 shares of common stock-equivalent units at no purchase price under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan.
Each restricted stock unit represents one share of Myriad Genetics common stock and will vest upon the earlier of the first anniversary of the grant date or the next annual meeting of stockholders. After this award, Newcomer directly holds 191,842 shares or share-equivalent units in total.
Davis Mark Steven reported acquisition or exercise transactions in this Form 4 filing.
Myriad Genetics director Mark Steven Davis received a grant of 59,701 restricted stock units (RSUs) of common stock. The award was granted under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan and carries no purchase price.
Each RSU represents a right to receive one Myriad Genetics common share and will vest upon the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant. After this grant, Davis directly holds 106,665 shares of common stock, reflecting his updated ownership position.
Phanstiel S. Louise reported acquisition or exercise transactions in this Form 4 filing.
Myriad Genetics Inc. director S. Louise Phanstiel received an equity award of 59,701 restricted stock units (RSUs). The award was granted under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan at no cash cost to the director.
Each RSU represents a contingent right to receive one share of Myriad Genetics common stock and will vest upon the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant. After this grant, Phanstiel directly holds 341,652 shares of common stock, reflecting her updated ownership position including the new award.
Dreismann Heinrich reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC director Heinrich Dreismann received a grant of 59,701 restricted stock units of common stock. The award was made at no cash cost per share and is part of the company’s 2026 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a right to receive one common share and will vest upon the earlier of the first anniversary of the grant date or the next annual stockholder meeting. Following this equity award, Dreismann directly holds 231,145 shares of Myriad Genetics common stock.
Reitan Colleen F reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC director Colleen F. Reitan received an equity grant of 59,701 shares of common stock in the form of restricted stock units under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan. Following this award, she directly holds 152,030 shares of common stock.
Each restricted stock unit represents a right to receive one share of common stock and will vest upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders after the grant. This is a compensation-related award rather than an open-market share purchase.